Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension

Key Points Question Is intensive blood pressure management among older patients with hypertension cost-effective? Findings This economic evaluation with a Markov model and extensive sensitivity analyses estimated the incremental lifetime medical costs, quality-adjusted life-years (QALYs), and cost-effectiveness of intensive vs standard blood pressure targets for older patients with hypertension in China, the US, and the UK. Intensive blood pressure control produced fewer cardiovascular events and low costs per QALY gained, well below the typical willingness-to-pay thresholds, and the cost-effective advantages were consistent over various clinical scenarios across different countries. Meaning These clinical and economic findings suggest intensive blood pressure control is cost-effective in older adults.

[1]  V. Cornelius,et al.  Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension , 2022, JAMA internal medicine.

[2]  Weili Zhang,et al.  Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.

[3]  J. Danesh,et al.  SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. , 2021, European heart journal.

[4]  C. Bulpitt,et al.  SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. , 2021, European heart journal.

[5]  Duolao Wang,et al.  Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study , 2021, PLoS medicine.

[6]  Xu Yang,et al.  Changing Paradigm for Vertigo/Dizziness Patients: a Retrospective Before-After Study from Tertiary Hospitals in Northwestern China , 2021, Journal of General Internal Medicine.

[7]  G. Lip,et al.  Atrial Fibrillation in the United Kingdom: Predicting Costs of an Emerging Epidemic Recognising and Forecasting the Cost Drivers of Atrial Fibrillation-related costs. , 2020, European heart journal. Quality of care & clinical outcomes.

[8]  R. McManus,et al.  Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk , 2020, Hypertension.

[9]  Shunping Li,et al.  Applying SF-6D to measure health state utilities among the middle and old aged patients with hypertension in China , 2020, Health and Quality of Life Outcomes.

[10]  Xiangli Cui,et al.  Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China , 2020, BMC Health Services Research.

[11]  D. King,et al.  Estimated societal costs of stroke in the UK based on a discrete event simulation , 2019, Age and ageing.

[12]  M. Burnier,et al.  Adherence in Hypertension. , 2019, Circulation research.

[13]  Q. Hua,et al.  2019 Chinese guideline for the management of hypertension in the elderly , 2019, Journal of geriatric cardiology : JGC.

[14]  Mohammad Hosein Farzaei,et al.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[15]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[16]  D. Siscovick,et al.  Cost-effectiveness analysis of intensive hypertension control in China. , 2018, Preventive medicine.

[17]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[18]  P. Ludman,et al.  Clinical outcomes and costs of cardiac revascularisation in England and New York state , 2018, Open Heart.

[19]  C. O’Seaghdha,et al.  Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. , 2017, The New England journal of medicine.

[20]  James R. Powell,et al.  Cost‐Effectiveness of Intensive versus Standard Blood‐Pressure Control , 2017 .

[21]  Nicolas R. Ziebarth,et al.  End-Of-Life Medical Spending In Last Twelve Months Of Life Is Lower Than Previously Reported. , 2017, Health affairs.

[22]  T. Wilt,et al.  Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians , 2017, Annals of Internal Medicine.

[23]  A. Schuler,et al.  Cost-effectiveness of Intensive Blood Pressure Management. , 2016, JAMA cardiology.

[24]  Xueli Yang,et al.  Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China) , 2016, Circulation.

[25]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[26]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[27]  Jiang He,et al.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.

[28]  Rosanne Raso,et al.  Changing a paradigm. , 2015, Nursing management.

[29]  R. Burge,et al.  Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis , 2015, ClinicoEconomics and outcomes research : CEOR.

[30]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[31]  D. Newman-Toker,et al.  Rising annual costs of dizziness presentations to U.S. emergency departments. , 2013, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[32]  D. Malone,et al.  Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation , 2013, Stroke.

[33]  Shanlian Hu,et al.  Economic Burden of Individual Suffering from Atrial Fibrillation-Related Stroke in China. , 2013, Value in health regional issues.

[34]  A. Bower,et al.  The direct and indirect costs of long bone fractures in a working age US population , 2013, Journal of medical economics.

[35]  J. Brazier,et al.  Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[36]  H. Jin,et al.  Cost-effectiveness of diagnostic approaches to vasovagal syncope. , 2010, Chinese medical journal.

[37]  Yi Fang,et al.  Acute Kidney Injury in a Chinese Hospitalized Population , 2010, Blood Purification.

[38]  Li Yang,et al.  Economic burden of cardiovascular diseases in China , 2008, Expert review of pharmacoeconomics & outcomes research.

[39]  M. Palta,et al.  US Norms for Six Generic Health-Related Quality-of-Life Indexes From the National Health Measurement Study , 2007, Medical care.

[40]  Patrick W. Sullivan,et al.  Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[41]  Paul C Nagle,et al.  Review of recent US cost estimates of revascularization. , 2004, The American journal of managed care.

[42]  Antonio Addis,et al.  Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. , 2002, Clinical therapeutics.

[43]  M. Marcus,et al.  The heart in hypertension. , 1992, The New England journal of medicine.

[44]  R. C. C. Coutinho Quality of life of patients with hypertension , 2012 .